New Mass Spectrometry Portfolio Leverages Enhanced Hardware and Software to Advance Quantitative Analysis

New Mass Spectrometry Portfolio: Lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can now benefit from accelerated throughput and improved sensitivity to meet rapidly changing regulatory requirements and provide the fast responses needed for tackling emerging human and environmental health risks.

The Thermo Scientific TSQ Plus triple quadrupole mass spectrometer (MS) portfolio increases workflow throughput through superior data acquisition and polarity switching speeds. The improved low-mass product ion transmission efficiency enhances sensitivity for key target applications. The new portfolio, which consists of the TSQ Altis Plus, TSQ Quantis Plus and TSQ Fortis Plus MS, can be used across a range of applications, from targeted quantitation to cutting-edge research. Intuitive mass calibration routines and method optimization, in combination with market-leading chromatography and data processing software solutions, offers improved ease of use to address future analytical challenges.

“Laboratories performing routine quantitative experiments continue to need to identify new compounds of interest across industries, such as pharma, food and environmental, resulting in rapidly changing regulations and lower detection limits,” said August Specht, vice president, research and development, chromatography and mass spectrometry, Thermo Fisher. “In order to protect consumer and environmental health, laboratories need to provide comprehensive workflows to address evolving requirements, and the TSQ Plus triple quadrupole MS portfolio has been designed to deliver.”

Professor Julijana Ivanisevic, University of Lausanne, said “The TSQ Altis Plus platform is a step forward toward omics-scale, quantitative MS-based methodology for in-depth investigation of metabolism. The unprecedented acquisition speed of the TSQ Altis Plus allows us to maximize the metabolome coverage and significantly enhances the peak definition, essential for accurate quantification. The TSQ Altis Plus mass spectrometer allows for robust quantification of low abundant species, thus complementing the comprehensiveness of measured metabolite signature. This increase in productivity, along with the quantitative aspect, is crucial for metabolic phenotyping of human populations – a prerequisite for the transfer to clinical settings.”

Users of the TSQ Plus triple quadrupole MS portfolio will benefit from:

  • Increased system uptime due to enhanced quadrupole mass stability.
  • Direct instrument method transfers from the existing Thermo Scientific TSQ MS portfolio to the TSQ Plus MS portfolio, enabling simplified transfers.
  • Integration with mzCloud database to provide Selective Reaction Monitoring (SRM) transition information with predicted collision energy.
  • Integration with industry-leading liquid- and ion-chromatography systems and software, delivering powerful quantitative application solutions.
  • Other news from the company today here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version